In a statement, Sanofi indicated that the operation is framed within its strategy of orienting the business towards immunology and aligning its global industrial network.
The agreement with Adamed Pharma ensures the continuity of productive activity at the Riells i Viabrea center, as well as the maintenance of the more than 200 existing jobs.
Furthermore, the deal guarantees the supply of the medicines currently manufactured at the facility, which boasts over 50 years of industrial history in the region.
